sdLDL

Small dense low-density lipoprotein particles: clinically relevant?

This review focused on the clinical significance of small dense low-density lipoprotein (sdLDL) particles in cardiovascular disease risk. Researchers found that higher sdLDL levels are associated with increased ASCVD risk, independent of other lipid factors. The review calls for further studies to clarify the clinical benefits of measuring and reducing sdLDL levels.

Update on the laboratory investigation of dyslipidemias.

This review examined the evolving role of clinical laboratories in assessing cardiovascular disease risk through lipid measurements. Researchers pointed out that current methods for measuring LDL cholesterol have limitations and suggested that measuring LDL particle size and concentration could provide better risk predictions. The review calls for robust methods to evaluate lipoprotein subclasses and their role in cardiovascular risk assessment.

The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.

This study reviewed the impact of LDL size on cardiovascular risk and the effects of fibrate treatments on LDL subclasses. Researchers found that fibrates can beneficially modulate LDL size, particularly fenofibrate, which was noted to be effective in patients at higher cardiovascular risk. The findings support the importance of LDL quality in cardiovascular risk management.

Association of LDL-cholesterol subfractions with cardiovascular disorders: a systematic review.

This systematic review evaluated the association between low-density lipoprotein (LDL) subfractions and cardiovascular disorders. Researchers concluded that higher LDL particle numbers, particularly small dense LDL, are consistently linked to increased cardiovascular disease risk. The review suggests that assessing LDL subclasses may serve as a valuable biomarker for cardiovascular disease diagnosis.

Estimated Small, Dense LDL Cholesterol and Atherosclerotic Cardiovascular Risk in the UK Biobank.

Zubiran Rafael, et al. · Arteriosclerosis, thrombosis, and vascular biology · 2025

Researchers found that estimated small, dense low-density lipoprotein cholesterol (E-sdLDL-C) is a significant predictor of atherosclerotic cardiovascular disease (ASCVD) risk, outperforming traditional LDL cholesterol measurements. The study indicated that elevated E-sdLDL-C levels, especially when discordant with other lipid measures, correlate with a higher risk of ASCVD. This suggests that E-sdLDL-C could enhance risk assessment in cardiovascular health.

Atherogenic low-density lipoprotein and cardiovascular risk.

Researchers reviewed the evolving understanding of low-density lipoprotein (LDL) and its role in cardiovascular risk. They found that small dense LDL is linked to increased risk of cardiovascular disease, emphasizing the importance of comprehensive lipoprotein profiling. The review suggests that a panel of biomarkers may help predict future cardiovascular events.

Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study.

Researchers investigated the potential of estimated small dense low-density lipoprotein cholesterol (EsdLDL-C) as a biomarker for assessing the severity of hepatic steatosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study found that EsdLDL-C was an independent risk factor for moderate-to-severe hepatic steatosis, with a predictive value indicated by an area under the curve of 0.825. This suggests EsdLDL-C could be a cost-effective biomarker for high-risk MASLD patients.